MyFinsight
Home
Blog
About
Contact
Proceeds from issuance of
long-term debt, net of...
$173,250K
Net proceeds from
underwritten public offering
$121,974K
Proceeds from issuance of
common stock from...
$591K
Net cash provided by
financing activities
$66,640K
Canceled cashflow
$229,175K
Net increase
(decrease) in cash and cash...
$50,932K
Canceled cashflow
$15,708K
Repayment of long-term
debt
$229,047K
Payment of employee tax
obligations related to...
-$128K
Prepaid expenses and
other current assets
-$6,918K
Stock-based compensation
$5,534K
Accrued interest on
revenue interest...
$3,543K
Other
-$1,605K
Amortization of debt discount
$844K
Loss on
extinguishment of debt
-$829K
Accrued
payment-in-kind interest on debt
$712K
Inventory
-$665K
Depreciation and
amortization
$110K
Operating right-of-use
assets and lease...
$10K
Net cash used in
operating activities
-$15,647K
Net cash used in
investing activities
-$61K
Canceled cashflow
$20,770K
Net loss
-$30,369K
Cash paid for
property and equipment
$61K
Accounts payable and
accrued expenses
-$3,124K
Accounts receivable, net
$2,596K
Other long-term
assets
$171K
Accrued interest
-$157K
Back
Back
Cash Flow
Phathom Pharmaceuticals, Inc. (PHAT)
Phathom Pharmaceuticals, Inc. (PHAT)
source: myfinsight.com